Skip to content

Ophtalé

Active Private limited companyfounded 2021active for 5 yearsRue du Fondry 19, 5651 WalcourtKBO/BCE: BE 0772.944.203 #7 company by total assets in Walcourt, Health and social work sector

Lifetime

4 annual accounts with figures on one time axis
peak of €294,735 in 2026
€294,735▲ 41.7%
peak of €95,656 in 2026
€95,656▲ 125%
peak of €233,640 in 2025
€233,640unchanged
€759,500▲ 6.1%
Board1 name since 2021
1 director
Documentsfilings and deeds
17-07-2026106 days before the deadline
2026micro format
Gross margin from €208,017 to €294,735Result from €42,519 to €95,656Dividend €95,656Cash from €144,477 to €288,555

Key points

from the 2026 annual accounts

Equity

€233,640 =
233,6402025+95,656Profit-95,656Dividend233,6402026

Ophtalé paid out €95,656 in dividends. That is 100% of the 2026 profit.

Result

€95,656 ▲ 125%
€42,5002025€95,7002026

The result rose in 2026 from €42,519 to €95,656.

Turnover

≈ €440,000 estimated

The micro format states no turnover.

Debts

€759,500 76% of the balance sheet
Financial debts 52%Suppliers 1%Taxes and wages 6%Other 41%

Of this, €367,016 falls due within a year.

Investments

€5,033 0.0 times depreciation
2023202420252026

Green is investment, beige is depreciation.

Position in the sector

23.5%

Lower solvency than 83% of companies in human health. The sector median is 71.4%, over 563 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 2,684 companies had the same profile as Ophtalé has now. Each dot stands for 7 companies, two years later.

97.2%
were still trading
1.3%
stopped another way
1.3%
went bankrupt
  • Small
  • 5 to 10 years old
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 2,684 companies, not a prediction for Ophtalé. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 100 sharesdeed of 31-08-2021
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0772944203
Incorporation Founding capital of €60,000, 100 shares · Founded by · appointed as director · published on 31-08-2021 · Gazette deed
First establishment OPHTALE, Rue du Fondry 19, Walcourt
All 11 events

Comparable companies

same main activity, similar in size and age
Company
Ophtalé Walcourt €1.0m €294,735 23.5% -
CMGEA AVICENNE Liège €1.0m €327,247 39.7% -
Dr. Tuytten Tom Zonhoven €0.9m €274,769 10.9% -
Dr. Sablon Adriaan Erpe-Mere €1.2m €294,778 36.1% -
Drs. van der Maas - De Lille Kortrijk €0.8m €321,880 36.6% -
Dr. Sarah Van Loo Stekene €1.0m €350,999 65.5% -
Clinique de la Vision Waterloo Waterloo €0.8m €284,955 29.6% -

These companies have the same main activity as Ophtalé: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €833,000 and €1.2m, founded between 2020 and 2022.

Official details

Source: KBO
Status
Active since 27-08-2021Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.321.424.6855651 Walcourt, since 27-08-2021
Financial year end
31 March
Peppol
Reachable since 22-12-2025
Company details

Annual accounts to 31-03-2026

€993,140▲ 4.6%
Filing
Filed on 17-07-2026, 106 days before the end of the filing period
Financials

Insights on Ophtalé

Ophtalé files the micro format. That format states no turnover. The gross margin rose from €140,474 in 2023 to €294,735 in 2026.

The balance sheet grew most from 2024 to 2026 through fixed assets.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Ophtalé

What is the company number of Ophtalé?
The company number of Ophtalé is 0772.944.203. The VAT number is the same number with BE in front: BE 0772.944.203.
Where is Ophtalé based?
The registered office is at Rue du Fondry 19, 5651 Walcourt.Company details
What does Ophtalé do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of Ophtalé?
Ophtalé is a private limited company (BV).
When was Ophtalé founded?
Ophtalé was founded on 27-08-2021.
Is Ophtalé still active?
Yes, Ophtalé is an active enterprise in the KBO register.
What is the turnover of Ophtalé?
The turnover in financial year 2026 is about €440,000. This figure is estimated from the gross margin of €294,735 and 31 comparable companies (NACE 86220). It probably lies between €390,000 and €620,000.Financials
Is Ophtalé profitable?
In financial year 2026, Ophtalé made a profit of €95,656.
Where can I find the annual accounts of Ophtalé?
Ophtalé filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
When are the next annual accounts of Ophtalé due?
Ophtalé must file the annual accounts for financial year 2027 by 31-10-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.